<div id="readability-page-1"><p><span>Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report)</span> had its target price dropped by investment analysts at HC Wainwright  from $5.00 to $3.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. HC Wainwright's target price would indicate a potential upside of 260.14% from the stock's current price.</p><p>TNYA has been the topic of several other research reports. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Tenaya Therapeutics in a report on Wednesday, October 8th. Chardan Capital cut their price objective on shares of Tenaya Therapeutics from $9.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday. Four analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $5.50.</p><div><p><span></span><span>Get <strong>Tenaya Therapeutics</strong> alerts:</span></p></div><p><b>View Our Latest Stock Analysis on Tenaya Therapeutics</b></p><h2>Tenaya Therapeutics Price Performance</h2><p>TNYA traded down $0.53 on Friday, reaching $0.83. 42,596,872 shares of the stock were exchanged, compared to its average volume of 3,261,775. The company's 50-day moving average price is $1.51 and its 200 day moving average price is $1.11. The firm has a market capitalization of $138.70 million, a PE ratio of -1.06 and a beta of 3.13. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $2.95. </p><p>Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03.  As a group, equities analysts forecast that  Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On Tenaya Therapeutics</h2><p>Several large investors have recently made changes to their positions in the company. Woodline Partners LP raised its position in shares of  Tenaya Therapeutics by 30,563.2% in the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock worth $3,373,000 after acquiring an additional 5,896,873 shares during the period.  Millennium Management LLC increased its stake in shares of  Tenaya Therapeutics by 561.7% in the 3rd quarter. Millennium Management LLC now owns 4,504,592 shares of the company's stock valued at $7,297,000 after purchasing an additional 3,823,848 shares in the last quarter.  AQR Capital Management LLC acquired a new position in  Tenaya Therapeutics in the 1st quarter worth about $442,000.  Schonfeld Strategic Advisors LLC purchased a new position in shares of  Tenaya Therapeutics during the 3rd quarter valued at approximately $755,000.  Finally, GSA Capital Partners LLP purchased a new position in  Tenaya Therapeutics during the third quarter valued at $748,000. 90.54% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Tenaya Therapeutics</h2> (Get Free Report)<p>Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Tenaya Therapeutics</li><li>What is Put Option Volume?</li><li>Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic</li><li>Technology Stocks Explained: Here's What to Know About Tech</li><li>Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?</li><li>Special Purpose Acquisition Company (SPAC) What You Need to Know </li><li>2 Small-Cap Biotechs That Could Reward Patient Investors</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ZQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ZQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tenaya Therapeutics Right Now?</h2><p>Before you consider Tenaya Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.</p><p>While Tenaya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TNYA

<p>HC Wainwright lowered Tenaya Therapeutics' price target from $5.00 to $3.00, maintaining a "buy" rating. The stock has a potential upside of 260.14% from its current price. Other analysts have mixed ratings, with a consensus "Moderate Buy" and a price target of $5.50. The stock traded at $0.83, with significant institutional ownership. Tenaya focuses on heart disease therapies, with several products in clinical trials.</p>

Tenaya Therapeutics (NASDAQ:TNYA) Given New $3.00 Price Target at HC Wainwright